Literature DB >> 21768811

Linezolid does not show advantages over vancomycin in modulating the pulmonary immune response: how should we conciliate these new findings with the Zephyr trial results?

Andre C Kalil.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21768811     DOI: 10.1097/CCM.0b013e318221741c

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  2 in total

1.  Linezolid is superior to vancomycin in experimental pneumonia caused by Superantigen-Producing staphylococcus aureus in HLA class II transgenic mice.

Authors:  Melissa J Karau; Ashenafi Y Tilahun; Suzannah M Schmidt; Chad R Clark; Robin Patel; Govindarajan Rajagopalan
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

2.  Linezolid for the treatment of hospital-acquired pneumonia in a Chinese tertiary hospital.

Authors:  Beth A Lesher; Zhengyin Liu; Yixi Chen; Xin Gao
Journal:  Clinicoecon Outcomes Res       Date:  2015-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.